Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04852224
Other study ID # 0261-21-FB
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2021
Est. completion date April 26, 2023

Study information

Verified date October 2023
Source University of Nebraska
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this study is to compare changes in neurocognitive function across a 12-month period between three groups: (1) men treated with androgen deprivation therapy (ADT) for prostate cancer (PCa); (2) men under active surveillance for PCa; and (3) men without a history of cancer.


Description:

Aim 1: This study will examine differences in neurocognitive function (cognitive performance, brain structural integrity) from baseline (within 30 days of ADT initiation or 90 days of diagnosis) to 6- and 12-month follow-up. Aim 2: Examine group differences in components of frailty (e.g., lean mass, muscle strength, physical function, fatigue, physical activity) from baseline to 6- and 12-month follow-up. Men will be recruited for this study if they are (1) recently diagnosed with PCa and scheduled to receive 6-months or more of ADT (ADT+ group, n=20), (2) recently diagnosed with PCa and under active surveillance (ADT- group, n=20), or (3) healthy men without a history of cancer (PCa- group, n=20). Eligible men (N=60) will be scheduled for two or three testing appointments at each testing timepoint. To assess Aim 1, participants will complete measures at baseline (M0), 6-month follow-up (M6), and 12-month follow-up (M12). Aim 1 measures include: neurocognitive tasks, functional magnetic resonance imaging (optional; n=10 ADT+ and n=10 ADT- only), and questionnaires. To assess Aim 2, outcomes indicated as components of frailty syndrome will be measured, including: dual-energy X-ray absorptiometry (e.g., appendicular lean mass), upper and lower body dynamometry, physical function and functional capacity, questionnaires (i.e., fatigue surveys), and physical activity monitoring (i.e., accelerometry). Findings from this study will build upon the scientific framework for the potential frailty pathway of cancer-associated cognitive decline in PCa patients in order to develop future evidence-based interventions to manage cognitive impairment in men diagnosed with PCa.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date April 26, 2023
Est. primary completion date April 11, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 19 Years and older
Eligibility Inclusion Criteria: - Telephone Interview of Cognitive Status (TICS-M) performance above impaired range (=21) Group-specific criteria: - First time, primary diagnosis of prostate cancer (ADT+ and ADT-) - Diagnosed within past 30 days (ADT-) - Scheduled to receive = 6-months androgen deprivation therapy and have not received >30 days of androgen deprivation therapy (ADT+) - Men without a history of cancer who are within one year of age of ADT+ participants (PCa-) Exclusion Criteria: - Second cancer diagnosis (excluding non-invasive skin cancers) - History of stroke, transient ischemic attack, neurological disorder, or brain surgery involving tissue removal - Unable to walk without assistance - Unwilling to complete study requirements - Body weight greater than 300 pounds (DXA requirement) - Moderate-intensity physical activity = 150 minutes per week - Upper and lower body strength training = 2 days per week - Unable to read in English

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Androgen deprivation therapy
Prostate cancer survivors in the ADT+ group will have been prescribed androgen deprivation therapy for a period of 6-months or more by their treating oncologist prior to consent for this study.

Locations

Country Name City State
United States University of Nebraska Medical Center Omaha Nebraska

Sponsors (2)

Lead Sponsor Collaborator
University of Nebraska American College of Sports Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in inhibitory control Change in interference score on Stroop task, with negative values indicating lower inhibitory control. The Stroop task interference score is a continuous variable with no minimum or maximum value. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Primary Change in cognitive flexibility Change in reaction time on Task-switch task, with higher values indicating lower cognitive flexibility. The Task-switch reaction time is a continuous variable with no minimum or maximum value. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Primary Change in executive function Change in completion time on Trails B task, with higher values indicating lower executive function. Trails B completion time is a continuous variable with no minimum or maximum value. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Primary Change in spatial working memory reaction time Change in reaction time on spatial working memory task, with faster reaction times indicating better spatial working memory. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Primary Change in short term memory Change in accuracy on N-Back task, with higher accuracy indicating better short-term memory. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Primary Change in processing speed Change in accuracy on Attentional Blink task, with higher accuracy indicating faster processing speed. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Primary Change in verbal memory Change in number recalled on Hopkins Verbal Learning Task, with greater number of items recalled indicating better verbal memory. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Primary Change in visuospatial function Change in accuracy on Benton Judgement of Line Orientation task, with higher accuracy indicating better visuospatial function. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Primary Change in white matter integrity Change in fractional anisotropy as measured by diffusion MRI. Baseline (M0), 6-month follow-up (M6)
Primary Change in brain volume Change in mean cortical thickness of brain regions of interest as measured by an anatomical MRI brain scan. Baseline (M0), 6-month follow-up (M6)
Primary Change in resting state functional connectivity Change in within-network pairwise correlation estimates as measured using a multiband echo planar imaging (mb-EPI) functional MRI sequence. Baseline (M0), 6-month follow-up (M6)
Primary Change in self-reported cognitive function The perceived cognitive impairments subscale of the Functional Assessment in Cancer Therapy - Cognition (FACT-Cog) will be sued to measure self-reported cognition. Scores range from 0-72, with higher scores indicating better cognitive function. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Secondary Change in appendicular lean mass index Change in appendicular lean mass index (ALMI) as measured by dual-energy X-ray absorptiometry (DXA) with higher scores indicating more lean mass. Appendicular lean mass, as measured by DXA, will be divided by height to determine ALMI. ALMI score is a continuous variable with no minimum or maximum value. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Secondary Change in physical function The Short Physical Performance Battery (SPPB) will be used to assess physical function. Higher scores on the SPPB are indicative of better physical function. The SPPB has a minimum score of 0 and a maximum score of 12. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Secondary Change in functional capacity The Six Minute Walk Test (6MWT) will be used to measure functional capacity. The 6MWT is scored as distance walked in the 6 minutes with greater distance indicating greater functional capacity. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Secondary Change in upper body strength Change in grip strength as measured by hand grip dynamometry with higher scores indicating greater upper body strength. Hand grip strength is a continuous variable with no minimum or maximum value. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Secondary Change in lower body strength Change in quadriceps strength as measured by hand-held quadriceps dynamometry with higher scores indicating greater lower body strength. Quadriceps strength is a continuous variable with no minimum or maximum value. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Secondary Change in physical activity Change in daily minutes of moderate to vigorous physical activity (MVPA) will be measured via accelerometry with more minutes of daily MVPA indicating more physical activity. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
Secondary Change in cancer-related fatigue The Functional Assessment in Chronic Illness Therapy (FACIT) - Fatigue Scale will be used to measure cancer-related fatigue. Scores range from 0-52, with higher scores indicating less cancer-related fatigue. Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A